Exelixis Total Long Term Liabilities 2010-2024 | EXEL

Exelixis total long term liabilities for the quarter ending September 30, 2024 were $0.291B, a 15.07% increase year-over-year.

  • Exelixis total long term liabilities for 2023 were $0.284B, a 9.84% increase from 2022.
  • Exelixis total long term liabilities for 2022 were $0.259B, a 280.26% increase from 2021.
  • Exelixis total long term liabilities for 2021 were $0.068B, a 27.02% increase from 2020.

Exelixis Total Long Term Liabilities 2010-2024 | EXEL

  • Exelixis total long term liabilities for 2023 were $0.284B, a 9.84% increase from 2022.
  • Exelixis total long term liabilities for 2022 were $0.259B, a 280.26% increase from 2021.
  • Exelixis total long term liabilities for 2021 were $0.068B, a 27.02% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.6B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Jazz Pharmaceuticals (JAZZ)$7.7B